Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction

Molecular and Cellular Endocrinology

Volumn 378, Issue 1-2, 2013, Pages 23-28

  Jing, Fei ^a   Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipose tissue; Aldosterone; Angiotensin II; Metabolic sysdrome

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOSE; INSULIN; INTERLEUKIN 6; LOSARTAN; MINERALOCORTICOID RECEPTOR; RENIN; RENIN INHIBITOR; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; GLUCOSE TRANSPORT; HEART FAILURE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ALDOSTERONE; ANGIOTENSIN II; METABOLIC SYSDROME;

ADIPOCYTES; ADIPOSE TISSUE; ANGIOTENSIN II; ANIMALS; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84884532107     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.03.005     Document Type: Review

References (74)

1. Abu-Elheiga L., Oh W., Kordari P., Wakil S.J. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc. Natl. Acad. Sci. USA 2003, 100(18):10207-10212.
2. Ahima R.S. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006, 14(Suppl. 5):242S-249S.
3. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366(9491):1059-1062.
4. Anghel S.I., Bedu E., Vivier C.D., Descombes P., Desvergne B., Wahli W. Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2007, 282(41):29946-29957.
5. Barzilay J.I., Davis B.R., Cutler J.A., Pressel S.L., Whelton P.K., Basile J., Margolis K.L., Ong S.T., Sadler L.S., Summerson J. ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006, 166(20):2191-2201.
6. Campbell D.J., Habener J.F. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 1987, 121(5):1616-1626.
7. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V., Fabbri A., Zennaro M.C., Fève B. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011, 152(1):113-125.
8. Caprio M., Fève B., Claës A., Viengchareun S., Lombès M., Zennaro M.C. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007, 21(9):2185-2194.
9. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G., Novello M., Favret G., Melis A., Cavarape A., Sechi L.A. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 2006, 91(9):3457-3463.
10. Connell J.M., Davies E. The new biology of aldosterone. J. Endocrinol. 2005, 186(1):1-20.
11. Crandall D.L., Armellino D.C., Busler D.E., McHendry-Rinde B., Kral J.G. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999, 140(1):154-158.
12. Darimont C., Vassaux G., Ailhaud G., Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 1994, 135(5):2030-2036.
13. Devereux R.B., Dahlöf B., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., Rokkedal J., Harris K.E., Edelman J.M., Wachtell K. Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110(11):1456-1462.
14. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens. Suppl. 2005, 23(1):S9-17.
15. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., de Kloet E.R., Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2(8618):986-989.
16. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H.S., Barthel A., Hauner H., McCann S.M., Scherbaum W.A., Bornstein S.R. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 2003, 100(24):14211-14216.
17. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369(9557):201-207.
18. Engeli S., Gorzelniak K., Kreutz R., Runkel N., Distler A., Sharma A.M. Co-expression of renin-angiotensin system genes in human adipose tissue. J. Hypertens. 1999, 17(4):555-560.
19. Fujimoto M., Masuzaki H., Tanaka T., Yasue S., Tomita T., Okazawa K., Fujikura J., Chusho H., Ebihara K., Hayashi T., Hosoda K., Nakao K. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004, 576(3):492-497.
20. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005, 10(1):15-22.
21. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242(4878):583-585.
22. Furuhashi M., Ura N., Takizawa H., Yoshida D., Moniwa N., Murakami H., Higashiura K., Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 2004, 22(10):1977-1982.
23. Gillespie E.L., White C.M., Kardas M., Lindberg M., Coleman C.I. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28(9):2261-2266.
24. Goodfriend T.L., Ball D.L., Egan B.M., Campbell W.B., Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004, 43(2):358-363.
25. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29(24):2959-2971.
26. Hausman D.B., DiGirolamo M., Bartness T.J., Hausman G.J., Martin R.J. The biology of white adipocyte proliferation. Obes. Rev. 2001, 2(4):239-254.
27. Hirata A., Maeda N., Hiuge A., Hibuse T., Fujita K., Okada T., Kihara S., Funahashi T., Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc. Res. 2009, 84(1):164-172. (Epub 2009 June 8).
28. Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
29. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
30. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
31. Iwai M., Tomono Y., Inaba S., Kanno H., Senba I., Mogi M., Horiuchi M. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am. J. Hypertens. 2009, 22(7):784-791.
32. Jeon J.H., Kim K.Y., Kim J.H., Baek A., Cho H., Lee Y.H., Kim J.W., Kim D., Han S.H., Lim J.S., Kim K.I., Yoon do Y., Kim S.H., Oh G.T., Kim E., Yang Y. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008, 22(5):1502-1511.
33. Jones B.H., Standridge M.K., Taylor J.W., Moustaïd N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am. J. Physiol. 1997, 273(1 Pt. 2):R236-R242.
34. Kalupahana N.S., Massiera F., Quignard-Boulange A., Ailhaud G., Voy B.H., Wasserman D.H., Moustaid-Moussa N. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring) 2011, 10.1038/oby.2011.299.
35. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., Ohashi K., Hibuse T., Fujita K., Yasui A., Hiuge A., Kumada M., Kuriyama H., Shimomura I., Funahashi T. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006, 70(10):1717-1724.
36. Lapointe N., Rouleau J.L. Cardioprotective effects of vasopeptidase inhibitors. Can. J. Cardiol. 2002, 18(4):415-420.
37. Lastra-Lastra G., Sowers J.R., Restrepo-Erazo K., Manrique-Acevedo C., Lastra-González G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin. Endocrinol. (Oxf.) 2009, 71(1):1-6.
38. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003, 169(2):203-214.
39. Marver D., Stewart J., Funder J.W., Feldman D., Edelman I.S. Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc. Natl. Acad. Sci. USA 1974, 71(4):1431-1435.
40. Marzolla, V., Armani, A., Zennaro, M.C., Cinti, F., Mammi, C., Fabbri, A., Rosano, G.M., Caprio, M., 2011. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol. Cell Endocrinol.
41. Massiéra F., Bloch-Faure M., Ceiler D., Murakami K., Fukamizu A., Gasc J.M., Quignard-Boulange A., Negrel R., Ailhaud G., Seydoux J., Meneton P., Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001, 15(14):2727-2729. (Epub 2001 October 15).
42. Matsushita K., Wu Y., Okamoto Y., Pratt R.E., Dzau V.J. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006, 48(6):1095-1102.
43. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell Endocrinol. 2010, 314(1):1-16.
44. Nagase M., Matsui H., Shibata S., Gotoda T., Fujita T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50(5):877-883.
45. Nagase M., Yoshida S., Shibata S., Nagase T., Gotoda T., Ando K., Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006, 17(12):3438-3446.
46. Ndisang J.F. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm. 2010, 2010:359732.
47. Neels J.G., Olefsky J.M. Inflamed fat: what starts the fire?. J. Clin. Invest. 2006, 116(1):33-35.
48. Olivares-Reyes J.A., Arellano-Plancarte A., Castillo-Hernandez J.R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell Endocrinol. 2009, 302(2):128-139.
49. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Görgün C., Glimcher L.H., Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
50. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348(14). 1309-2.
51. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 1999, 341(10):709-717.
52. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., Mortensen R.M. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 1999, 4(4):611-617.
53. Sabuhi R., Ali Q., Asghar M., Al-Zamily N.R., Hussain T. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am. J. Physiol. Renal Physiol. 2011, 300(3). F700-6.
54. Saint-Marc P., Kozak L.P., Ailhaud G., Darimont C., Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001, 142(1):487-492.
55. Scavo L.M., Karas M., Murray M., Leroith D. Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J. Clin. Endocrinol. Metab. 2004, 89(7):3543-3553.
56. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004, 30(6):487-496.
57. Schölkens B.A., Landgraf W. ACE inhibition and atherogenesis. Can. J. Physiol. Pharmacol. 2002, 80(4):354-359.
58. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109(17):2054-2057. (Epub 2004 April 26).
59. Schling P. Expression of angiotensin II receptors type 1 and type 2 in human preadipose cells during differentiation. Horm. Metab. Res. 2002, 34(11-12):709-715.
60. Shiuchi T., Iwai M., Li H.S., Wu L., Min L.J., Li J.M., Okumura M., Cui T.X., Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004, 43(5):1003-1010. (Epub 2004 March 22).
61. Skurk T., van Harmelen V., Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler. Thromb. Vasc. Biol. 2004, 24(7):1199-1203.
62. 1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am. J. Hypertens. 2008, 21(2):206-212.
63. Tsuchida A., Yamauchi T., Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin. J. Pharmacol. Sci. 2005, 97(2):164-170.
64. Tsuchiya K., Yoshimoto T., Hirono Y., Tateno T., Sugiyama T., Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes. Am. J. Physiol. Endocrinol. Metab. 2006, 291(4). E771-8.
65. Urbanet R., Pilon C., Calcagno A., Peschechera A., Hubert E.L., Giacchetti G., Gomez-Sanchez C., Mulatero P., Toffanin M., Sonino N., Zennaro M.C., Giorgino F., Vettor R., Fallo F. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 2010, 95(8):4037-4042.
66. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389(6651):610-614.
67. Wada T., Ohshima S., Fujisawa E., Koya D., Tsuneki H., Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 2009, 150(4):1662-1669.
68. Weir M.R. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. Clin. Ther. 2007, 29(9):1803-1824.
69. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J.K., Cushman S.W., Cooney G.J., Atcheson B., White M.F., Kraegen E.W., Shulman G.I. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 2002, 277(52):50230-50236.
70. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293(5535):1673-1677.
71. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N. Engl. J. Med. 2000, 342(3):145-153.
72. 2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005, 54(4):991-999.
73. Yvan-Charvet L., Quignard-Boulangé A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 2011, 79(2):162-168.
74. Zimmet P., Magliano D., Matsuzawa Y., Alberti G., Shaw J. The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 2005, 12(6):295-300.